Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

161. Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis.

Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis.

Scottish Medicines Consortium2014

162. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinolforthetreatmentofchronic kidneydisease:asystematicreview Nigel Fleeman, 1* Gerlinde Pilkington, 1 Yenal Dundar, 1 Kerry Dwan, 1 Angela Boland, 1 Rumona Dickson, 1 Hameed Anijeet, 2 Tom Kennedy 2 and Jason Pyatt 2 1 Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK 2 Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK *Corresponding author Declared (...) competing interests of authors: none Published June 2014 DOI: 10.3310/hta18400 Scientific summary AllopurinolforthetreatmentofCKD Health Technology Assessment 2014; Vol. 18: No. 40 DOI: 10.3310/hta18400 NIHR Journals Library www.journalslibrary.nihr.ac.ukScientificsummary Background The term chronic kidney disease (CKD) is used to describe abnormal kidney function (or structure) and is defined according to the presence or absence of kidney damage and level of kidney function. Traditionally serum

NIHR HTA programme2014

163. Allopurinol for the treatment of chronic kidney disease: a systematic review

Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Allopurinol for the treatment of chronic kidney disease: a systematic review Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R, Anijeet H, Kennedy T, Pyatt J. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technology Assessment 2014; 18(40): 106 Authors' objectives The aim of this systematic review was to address the following research question: does allopurinol reduce mortality, the progression of chronic kidney disease or cardiovascular risk in people with CKD? Given the importance

Health Technology Assessment (HTA) Database.2014

164. Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD)

Colestilan (BindRen) - treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD)

Scottish Medicines Consortium2014

166. Chronic kidney disease in adults: assessment and management

Chronic kidney disease in adults: assessment and management Chronic kidne Chronic kidney disease in adults: y disease in adults: assessment and management assessment and management Clinical guideline Published: 23 July 2014 nice.org.uk/guidance/cg182 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Chronic kidney disease in adults: assessment and management (CG182) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

National Institute for Health and Clinical Excellence - Clinical Guidelines2014

167. The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease

The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease The NxStage System One NX1000-1 home The NxStage System One NX1000-1 home haemodialysis de haemodialysis device for renal replacement vice for renal replacement ther therap apy in chronic kidne y in chronic kidney disease y disease Medtech innovation briefing Published: 19 November 2014 nice.org.uk/guidance/mib12 pathways Summary Summary The NxStage System One is a haemodialysis (...) in chronic kidney disease (MIB12) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 42Cost and resource use Cost and resource use Limited cost information is available for the NxStage System One. The Manufacturer, NxStage Medical, is unable to provide information on the purchase cost of the NxStage System One. Instead, it presents the cost on a price-per-treatment basis that takes a number of variables into account

National Institute for Health and Clinical Excellence - Advice2014

168. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. BACKGROUND: Calcimimetic agents lower abnormal serum parathyroid hormone (PTH) levels in people who have chronic kidney disease (CKD), but the benefits and harms on patient-level outcomes are uncertain. Since this review was first published in 2006 showing that evidence for calcimimetics was largely restricted to biochemical outcomes, additional studies have been conducted. This is an update of a review first (...) the Cochrane Renal Group's Specialised Register to complete this update. SELECTION CRITERIA: We included all RCTs of a calcimimetic administered to patients with CKD for the treatment of elevated serum PTH levels. DATA COLLECTION AND ANALYSIS: Data were extracted on all relevant patient-centred and surrogate outcomes. We summarised treatment estimates using random effects and expressed treatment effects as a risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI). MAIN RESULTS: Eighteen

Cochrane2014

169. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease Original Article Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease MATTHEW A ROBERTS Department of Renal Medicine, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia Correspondence: Dr Matthew Roberts, Dept of Nephrology, Box Hill Hospital, Eastern Health, Level 2, 5 Arnold St (...) , Box Hill, Vic. 3128, Australia. Email: matthew.roberts@easternhealth.org.au Accepted for publication 7 October 2013. Accepted manuscript online 15 October 2013. doi:10.1111/nep.12168 Elevated blood pressure is an important modi?able risk factor for both cardiovascular disease (CVD) and progression toend-stagekidneydisease(ESKD). 1 Muchtimeandeffortin chronic kidney disease (CKD) clinics is spent on measuring blood pressure, deciding whether to escalate treatment, and which agent to use. Blood

KHA-CARI Guidelines2014

170. KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease

KHA-CARI commentary on the KDIGO Clinical Practice Guideline for lipid management in chronic kidney disease Commentary KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease SUETONIA C PALMER, 1,2 GIOVANNI FM STRIPPOLI 2,3,4,5,6 and JONATHAN C CRAIG 2,3 1 Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand; 2 Cochrane Renal Group, 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales (...) of a private dialysis provider, Diaverum. Funding: Dr Palmer is funded by a Rutherford Discovery Fellowship from the Royal Society of New Zealand. Due to the markedly accelerated risks of cardiovascular disease for people who have chronic kidney disease (CKD), 1 lipid-lowering treatment represents a potentially effective intervention to reduce cardiovascular events, including death from cardiovascular disease. However, existing randomized trials have been inconsistent about whether statin therapy is bene

KHA-CARI Guidelines2014

171. Management of Chronic Kidney Disease (CKD) in Primary Care

Management of Chronic Kidney Disease (CKD) in Primary Care VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF CHRONIC KIDNEY DISEASE IN PRIMARY CARE Department of Veterans Affairs Department of Defense QUALIFYING STATEMENTS The Department of Veterans Affairs and the Department of Defense guidelines are based upon the best information available at the time of publication. They are designed to provide information and assist decision making. They are not intended to define a standard of care (...) interventions within these guidelines does not guarantee coverage of civilian sector care. Additional information on current TRICARE benefits may be found at www.tricare.mil or by contacting your regional TRICARE Managed Care Support Contractor. Version 3.0 – 2014 December 2014 Page 1 of 117 Prepared by: The Management of Chronic Kidney Disease Working Group With support from: The Office of Quality, Safety and Value, VA, Washington, DC & Office of Evidence Based Practice, US Army Medical Command Version 3.0

VA/DoD Clinical Practice Guidelines2014

172. Chronic Kidney Disease

Chronic Kidney Disease Chronic Kidney Disease -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Chronic Kidney Disease Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease (Endorsed, June 2014) The guideline, Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease , was developed by the American College of Physicians and endorsed by the American Academy of Family Physicians. Key (...) Recommendations Asymptomatic adults without risk factors for chronic kidney disease should not be screened for chronic kidney disease. Adults who are taking an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker should not be tested for proteinuria, whether or not they have diabetes. Adults with hypertension and stage 1 to 3 chronic kidney disease should be treated with either an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker. Adults with stage 1 to 3

American Academy of Family Physicians2014

173. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV

Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV IDSA : Management of Chronic Kidney Disease | | | | | > > ShareThis "Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected with HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America" Published: Clinical Infectious Diseases ; 2014 ; 59 : 96 -138 Abstract It is important to realize that guidelines cannot always (...) Be Managed in Patients With CKD or End-Stage Renal Disease? Recommendations We recommend that clinicians prescribe ART and encourage persistence with therapy in HIV-infected patients who have CKD or end-stage renal disease (ESRD), as ART reduces mortality but is underused in this patient population ( strong, moderate ). We recommend that clinicians use either the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation to estimate GFR or the Cockcroft-Gault equation to estimate creatinine clearance

Infectious Diseases Society of America2014

174. Point-of-Care creatinine testing for the detection and monitoring of chronic kidney disease

Point-of-Care creatinine testing for the detection and monitoring of chronic kidney disease NIHR Diagnostic Evidence Cooperative Oxford www.oxford.dec.nihr.ac.uk Diagnostic Evidence Co-operative Oxford Cooperative Oxford HR Diagnostics Evidence Cooperative Oxford Clinical Question: In the primary care setting, what is the accuracy and utility of creatinine point-of-care (POC) tests in the detection and monitoring of Chronic Kidney Disease (CKD), compared to standard practice using laboratory (...) of Chronic Kidney Disease Horizon Scan Report 0038 March 2014 Horizon Scan Report 0035 February 2014 d) Detection of acute on chronic renal failure and acute kidney injury (AKI) Existing Technology: Blood samples sent from GP for analysis in local hospital laboratory. Results subsequently sent back to general practice typically within 24 hours. Depending on significance of result, this may or may not be communicated to the patient by letter, telephone or in person. Benefits of POC creatinine testing

NIHR DEC Oxford2014

175. Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease

Cohort study: Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease Article Text Women's health Cohort study Hypertension during pregnancy is associated with increased risk of chronic and end-stage kidney disease Reem A Asad , Vesna D Garovic

Evidence-Based Nursing (Requires free registration)2014

176. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 (...) to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. RESULTS: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6

NEJM2013

177. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom (...) of hyperphosphataemia, associated with chronic kidney disease, in patients who had been receiving dialysis for an average of 38.2 months. Interventions The intervention was sevelamer carbonate (6.9g/day) for the initial treatment of hyperphosphataemia. The comparator was calcium-based phosphate binders, which were those most commonly used in the UK; it was assumed that 70% of patients received calcium acetate (5.3g/day) and 30% received calcium carbonate (4.9g/day). Location/setting UK/secondary care. Methods

NHS Economic Evaluation Database.2013

178. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials Blood Pressure Lowering Treatment (...) Trialists' Collaboration CRD summary This review found that blood pressure lowering was effective in preventing cardiovascular events, in people with a moderately reduced glomerular filtration rate. This was a large meta-analysis based on individual patient data, and its findings are very likely to be reliable. Authors' objectives To define the cardiovascular effects of lowering blood pressure, in people with and those without chronic kidney disease. Searching This was a collaborative prospective review

DARE.2013

179. [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents]

[Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different (...) erythropoiesis-stimulating agents] Terapias biológicas en el tratamiento de la anemia asociada a insuficiencia renal crónica: eficacia y seguridad comparada entre los agentes estimuladores de la eritropoyesis [Biological therapies in the treatment of anaemia associated with chronic kidney disease: a comparison of efficacy and safety of different erythropoiesis-stimulating agents] Abdel–Kader Martín, L; Castillo Muñoz, MA; Ubago Pérez, R; Vega Coca, MD; Rodríguez López, R Record Status This is a bibliographic

Health Technology Assessment (HTA) Database.2013

180. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis

Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A CRD summary The authors concluded that based on observational evidence, therapies with 1,25-dihydroxyvitamin D and analogues (...) were associated with reduced mortality in patients with chronic kidney disease, particularly in those suffering from secondary hyperparathyroidism. Due to the nature of observational studies, the findings should be considered to be preliminary. Authors' objectives To evaluate the association between the use of any kind of vitamin D therapy and the risk of all-cause and cardiovascular mortality in patients affected by chronic kidney disease. Searching PubMed, ClinicalTrials.gov and The Cochrane

DARE.2013